Manufacturing & Packaging

Company will also financially commit $15 million for those pursuing pharma manufacturing careers.

Merger with pharmacovigilance service provider helps company expands its end-to-end solutions in the region.

Demands for services in this sector have increased since last year’s Q1 Scientific acquisition, CDMO says.

Bourgoin hub broadens customer needs to also address commercial manufacturing.

Network aims to improve end-to-end supply chain visibility for the life sciences industry.

New facility—located on company’s Pennsylvania site—is part of three-part manufacturing contract with BARDA.

Rise in value attributed to the ongoing decentralization of pharmacies.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

Project addresses customer demand in GMP-powered advanced therapeutics.

New site is expected to complement CDMO’s commercial production experience.

Acquisition expands company’s eCTD submission capabilities.

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.

Following numerous successful trial runs, vaccine production is expected to reach 700 million.

Expansion expected to increase global capacity by 75%.

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.

Facility addition expected to increase production capacity of TNAs.

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.

South Korea facility expected to provide fill-finish capabilities.

New California plant expected to streamline medicine production.

Investment expected to establish additional cGMPs, expand CDMO services.

Joint venture expected to address pharma’s injectable drug-filling sector.

Collaboration to support biotech company’s clinical and commercial production efforts.

Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.

Saint-Beauzire complex dedicated to sterile liquid drug production.

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.

Location serves as the US flagship for company’s global pharma development network.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.